Cigna Group (CI)
(Delayed Data from NYSE)
$333.56 USD
+3.65 (1.11%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $333.53 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CI 333.56 +3.65(1.11%)
Will CI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CI
Select Medical (SEM) Expands Rehabilitation Services in Central PA
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
CI: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Implied Volatility Surging for Cigna (CI) Stock Options
Other News for CI
The Cigna Group Publishes 2023 ESG Report, Furthering Its Commitment to Advancing Better Health for All
The Cigna Group's Second Quarter 2024 Earnings Release Details
CVS, Cencora drop as Walgreens announces store closures
Cigna’s Strong Market Position and Growth Outlook Justify Buy Rating
Cigna, Humana started at overweight at Piper Sandler